Cryoport Q2 2026: 8% Revenue Growth, 779 Clinical Trials Supported
- Life Sciences Services revenue grew 15% year-over-year to $27.97 million; BioStorage/BioServices surged 25%.
- Cryoport supported 779 global clinical trials and 22 commercially approved cell and gene therapies as of June 30, 2026.
- Company achieved positive adjusted EBITDA in Q2 2026, marking a milestone on its pathway to sustainable profitability.
Operational Impact
Cryoport's 51-trial net increase and 25% BioStorage/BioServices growth reflect rising demand for integrated cold-chain logistics across CGT clinical pipelines, expanding its capacity to support Phase 3 advancement and commercial patient access.
Source: PR Newswire pharma category RSS